Urolithiasis Management Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032

Urolithiasis Management Devices Market by Type (Diagnostics [X-ray, Computed Tomography, Ultrasound, and Others] and Treatment [Shock Wave Lithotripters {Intracorporeal and Extracorporeal}, Ureteroscopes, {Semi-Rigid and Flexible}, Stone Retrieval Devices, and Others], End-User (Hospitals, Ambulatory Surgical Centers, and Others), Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising instances of urolithiasis or nephrolithiasis, sedentary lifestyle as a risk factor for the development of kidney stones and innovation in product design globally.

The urolithiasis management devices market was valued at USD 1.64 billion in 2024, growing at a CAGR of 4.27% during the forecast period from 2025 to 2032 to reach USD 2.29 billion by 2032. The demand for urolithiasis management devices is due to the rising cases of urolithiasis (nephrolithiasis), fueled by sedentary lifestyles, poor dietary habits, and inadequate fluid intake. This trend is further compounded by a growing geriatric population, which is more susceptible to stone formation and related complications, including an elevated risk of end-stage renal failure. In response, continued innovation in product design and other product development activities among the key market players is further escalating the overall market of urolithiasis management devices. Collectively, these factors are creating a favorable landscape for sustained market growth, positioning the urolithiasis management devices market for robust expansion from 2025 to 2032.

Urolithiasis Management Devices Market Dynamics:

According to the African Journal of Urology (2024), the cases of urolithiasis vary significantly across regions, with Western countries generally reporting higher rates compared to the Eastern hemisphere. Prevalence ranges from 1% to 5% in Asia, 5% to 9% in Europe, around 12% in Canada, and between 13% and 15% in the United States, while Saudi Arabia records an exceptionally high rate of 20.1%. These regional disparities, particularly the elevated prevalence in North America and parts of the Middle East, underscore a growing clinical need for effective stone management solutions. Factors such as sedentary lifestyles, poor dietary habits, obesity, and dehydration have led to an increasing global burden of kidney stones and related urinary tract stones. This growing patient population is driving the demand for both diagnostic and treatment solutions. As urolithiasis often presents with painful symptoms and has a high recurrence rate, healthcare providers are increasingly adopting minimally invasive technologies such as extracorporeal shock wave lithotripsy (ESWL), ureteroscopy (URS), and percutaneous nephrolithotomy (PCNL), which reduce recovery time and improve outcomes.

According to the World Health Organization (2024), by 2030, 1 in 6 people globally will be aged 60 years or older, and by 2050, this number is projected to double to 2.1 billion. Additionally, the population aged 80 and above is expected to triple between 2020 and 2050, reaching 426 million. This significant demographic shift is expected to substantially impact the urolithiasis management devices market, as aging is a well-established risk factor for kidney stone formation due to physiological changes, decreased mobility, and higher prevalence of comorbidities such as dehydration, metabolic disorders, and reduced renal function. As the elderly population grows, so does the demand for effective, minimally invasive stone management solutions tailored to this age group, thereby driving sustained growth in the market.

Moreover, product development activities among key players are also slated to witness considerable growth in the urolithiasis management devices market. For example, in March 2025, Calyxo, Inc., a medical device company focused on developing advanced solutions for kidney stone treatment, announced new data presentation at EAU25 supporting the safety, efficacy, and effectiveness of Steerable Ureteroscopic Renal Evacuation (SURE) using its CVAC System. This all-in-one stone clearance platform combines three distinct design features: microjet irrigation, simultaneous flow, and a large outflow lumen that work together to optimize fragment aspiration. Findings from two ex vivo studies and one real-world study collectively emphasize the CVAC System’s innovative mechanism of action and its ability to achieve superior stone clearance while maintaining safe intrarenal pressures and minimizing reflux.

Thus, due to the interplay of all the above-mentioned factors, the market for urolithiasis management devices is expected to increase in the forecast period from 2025 to 2032.

However, the risk of complications associated with these devices and the availability of alternative options, among others, are some of the key constraints that may limit the growth of the urolithiasis management devices market.

Urolithiasis Management Devices Market Segment Analysis:

Urolithiasis Management Devices Market by Type (Diagnostics [X-ray, Computed Tomography, Ultrasound, and Others] and Treatment [Shock Wave Lithotripters {Intracorporeal and Extracorporeal}, Ureteroscopes, {Semi-Rigid and Flexible}, Stone Retrieval Devices, and Others], End-User (Hospitals, Ambulatory Surgical Centers, and Others), Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the type segment of the urolithiasis management devices market, the extracorporeal shock wave lithotripters category is estimated to account for the largest market share in 2024. The rapid growth of this product category can be attributed to the features of the extracorporeal shock wave lithotripters.

The main benefit of extracorporeal shock wave lithotripsy is the non-invasive treatment, as it does not involve any skin incisions or the use of any invasive surgical instruments. Instead, shock waves are utilized to shatter the stone into tiny fragments that flow through the ureter and out of the bladder. It also has other advantages, such as reduced pain, quick recovery time, and shorter hospital stays.

These are suited for small stones as well as certain stones present in the upper portion of the ureter. Moreover, multiple stones can also be treated with extracorporeal shock wave lithotripsy. Therefore, it is expected that with such advantages offered by the extracorporeal shock wave urinary tract obstruction treatment devices, this technology is expected to increase its penetration in the coming years.

Additionally, the rising product development activities among market players are likely to drive the market for this category. For example, in May 2024, Huons Meditech made its debut as the first Korean company to participate in the American Urological Association 2024 Conference in Texas, where it unveiled its electromagnetic shock wave lithotripter ASADAL-M1. The ASADAL-M1, equipped with patented extracorporeal shock wave technology, demonstrated high efficacy in safely fragmenting urinary stones. The device received approvals from both the U.S. Food and Drug Administration and the European Medical Device Regulation.

Therefore, owing to the above-mentioned factors, the demand for the extracorporeal shock wave lithotripters category upsurges, thereby the sub-category is expected to witness considerable growth, eventually contributing to the overall growth of the urolithiasis management devices market during the forecast period from 2025 to 2032.

North America is expected to dominate the overall urolithiasis management devices market:

North America is projected to hold the largest share of the urolithiasis management devices market in 2024, driven by several key factors. This is attributed to the rising cases of kidney stones, highlighting the growing demand for effective management solutions. This demand is further amplified by technological advancements, regulatory approvals, and the strong market presence of key players, along with sustained investment in healthcare infrastructure and ongoing innovation in product development, all of which are expected to drive the urolithiasis management devices market during the forecast period from 2025 to 2032.

According to the American Urological Association (2024), nearly 1 in 11 individuals in the U.S. experience kidney stones at some point in their lives, with evidence indicating a rising incidence over time. This growing patient population is directly contributing to the expanding demand for urolithiasis management devices, as more individuals require effective diagnostic, treatment, and stone removal solutions. The increasing prevalence underscores the need for advanced, minimally invasive technologies such as laser lithotripters, ureteroscopes, and stone retrieval systems, driving innovation and investment in the market to meet the escalating clinical burden.

Additionally, the rising product development activities by regulatory bodies in the region will further boost the market for urolithiasis management devices. For example, in April 2024, Olympus Corporation announced FDA 510(k) clearance for its RenaFlex single-use ureteroscope system. RenaFlex offers access and visualization in the urinary tract to diagnose and treat urinary diseases and disorders, such as kidney stones.

Therefore, the interplay of all the aforementioned factors above would provide a conducive growth environment for the North America region in the urolithiasis management devices market.

Urolithiasis Management Devices Market Key Players:

Some of the key market players operating in the urolithiasis management devices market include Boston Scientific Corporation, EMS Urology, Advin Health Care, Inceler Medikal Co. Ltd., Walz Elektronik GmbH, DirexGroup, Medispec Ltd., Richard Wolf GmbH, STORZ MEDICAL AG, Olympus Corporation, GE Healthcare, ESAOTE SPA, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., BK Medical Holding Company, Inc., Hitachi Medical Systems, Laborie, DRAMIŃSKI S. A., ACE Medical Devices Pvt. Ltd., Siemens Healthcare Private Limited, Vimex Sp. z o.o., and others.

Recent Developmental Activities in the Urolithiasis Management Devices Market:

• In December 2024, the RELIEF™ ureteral stent received FDA clearance as the first and only stent approved specifically for the prevention of vesicoureteral reflux, a key contributor to patient discomfort. Its distinctive suture-based design enables the ureteral orifice to open and close naturally, effectively reducing the risk of reflux.
• In May 2024, Dornier MedTech introduced UroGPT, a first-of-its-kind artificial intelligence tool designed to assist kidney stone patients. It is developed in collaboration with leading urologists. UroGPT represents a significant step in the company’s commitment to harnessing digital innovation to deliver patient-centric solutions. The app offers urology patients on-demand guidance and practical insights, helping them better understand and manage their condition with confidence.

Key takeaways from the urolithiasis management devices market report study

• Market size analysis for the current urolithiasis management devices market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the urolithiasis management devices market.
• Various opportunities available for the other competitors in the urolithiasis management devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current urolithiasis management devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for urolithiasis management devices market growth in the future?

Target audience who can benefit from this urolithiasis management devices market report study

• Urolithiasis management device product providers
• Research organizations and consulting companies
• Urolithiasis management devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in urolithiasis management devices
• Various end-users who want to know more about the urolithiasis management devices market and the latest technological developments in the urolithiasis management devices market.

Frequently Asked Questions for the Urolithiasis Management Devices Market:

1. What are urolithiasis management devices?

• Urolithiasis management devices are specialized medical tools used to diagnose, fragment, remove, or facilitate the passage of urinary stones (kidney stones) from the urinary tract. They support both non-invasive and minimally invasive procedures, enhancing treatment precision, reducing recovery time, and improving patient outcomes in managing kidney, ureteral, and bladder stones.

2. What is the market for urolithiasis management devices?

• The urolithiasis management devices market was valued at USD 1.64 billion in 2024, growing at a CAGR of 4.27% during the forecast period from 2025 to 2032 to reach USD 2.29 billion by 2032.

3. What are the drivers for the urolithiasis management devices market?

• The demand for urolithiasis management devices is due to the rising cases of urolithiasis (nephrolithiasis), fueled by sedentary lifestyles, poor dietary habits, and inadequate fluid intake, which has significantly increased the clinical burden of kidney stones. This trend is further compounded by a growing geriatric population, which is more susceptible to stone formation and related complications, including an elevated risk of end-stage renal failure. In response, continued innovation in product design. Collectively, these factors are creating a favorable landscape for sustained market growth, positioning the urolithiasis management devices market for robust expansion from 2025 to 2032.

4. Who are the key players operating in the urolithiasis management devices market?

• Some of the key market players operating in the urolithiasis management devices market include Boston Scientific Corporation, EMS Urology, Advin Health Care, Inceler Medikal Co. Ltd., Walz Elektronik GmbH, DirexGroup, Medispec Ltd., Richard Wolf GmbH, STORZ MEDICAL AG, Olympus Corporation, GE Healthcare, ESAOTE SPA, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., BK Medical Holding Company, Inc., Hitachi Medical Systems, Laborie, DRAMIŃSKI S. A., ACE Medical Devices Pvt. Ltd., Siemens Healthcare Private Limited, Vimex Sp. z o.o., and others.

5. Which region has the highest share in the urolithiasis management devices market?

• North America is projected to hold the largest share of the urolithiasis management devices market in 2024, driven by several key factors. This is attributed to the rising cases of kidney stones, highlighting the growing demand for effective management solutions. This demand is further amplified by technological advancements, regulatory approvals, and the strong market presence of key players, along with sustained investment in healthcare infrastructure and ongoing innovation in product development, all of which are expected to drive the urolithiasis management devices market during the forecast period from 2025 to 2032.

This product will be delivered within 2 business days.